


### Lower Pore Diameters Result in Broader Peaks and Decreased Sensitivity


<b>column:</b>	BIOshell™ IgG 1000 Å C4, 10 cm x 2.1 mm I.D., 2.7 µm; FPP 300 Å C4, 10 cm x 2.1 mm I.D., 1.7 µm
<b>mobile phase:</b>	[A] water (0.1% (v/v) difluoroacetic acid); [B] acetonitrile (0.1% (v/v) difluoroacetic acid)
<b>gradient:</b>	Hold at 22% B for 2 min; 22% B to 52% B in 15 min
<b>flow rate:</b>	0.3 mL/min
<b>column temp.:</b>	75 °C
<b>detector:</b>	UV, 215 nm
<b>injection:</b>	5 µL
<b>sample:</b>	IgG4, 100 µg/mL, water



The large pores of the BIOshell™ IgG 1000 Å C4 column allows improved access to the stationary phase resulting in narrower peaks.

### Effect of Phase Chemistry on Protein Selectivity


<b>column:</b>	BIOshell™ IgG 1000 Å C4, 15 cm x 2.1 mm I.D., 2.7 µm; BIOshell™ IgG 1000 Å C18, 15 cm x 2.1 mm I.D., 2.7 µm; BIOshell™ IgG 1000 Å Diphenyl, 15 cm x 2.1 mm I.D., 2.7 µm
<b>mobile phase:</b>	[A] 2:10:88 n-propanol/acetonitrile/water (0.1% v/v difluoroacetic acid); [B] 70:20:10 n-propanol/acetonitrile/water (0.1% v/v difluoroacetic acid)
<b>gradient:</b>	16% B to 26% B in 20 min
<b>flow rate:</b>	0.2 mL/min
<b>column temp.:</b>	80 °C
<b>detector:</b>	UV, 280 nm
<b>injection:</b>	2 µL
<b>sample:</b>	Denosumab, 2 mg/mL, water (0.1% v/v trifluoroacetic acid)



Monoclonal antibodies are unique molecules and therefore can interact differently with different phase chemistries. The numbered peaks correspond to IgG2 disulfide bond variants.

### Choice of Ion-Pairing Reagent Is Crucial to Enhanced Resolution and Sensitivity

<b>column:</b>	BIOshell™ IgG 1000 Å C4, 15 cm x 2.1 mm I.D., 2.7 µm
<b>mobile phase:</b>	[A] Water (0.1% v/v formic acid, difluoroacetic acid, or trifluoroacetic acid, as indicated) [B] 20:80 Water:Acetonitrile (0.1% v/v formic acid, difluoroacetic acid, or trifluoroacetic acid, as indicated)
<b>gradient:</b>	35% B to 47.5% B in 12 min
<b>flow rate:</b>	0.4 mL/min
<b>column temp.:</b>	80 °C
<b>detector:</b>	UV, 280 nm
<b>injection:</b>	2 µL
<b>sample:</b>	Trastuzumab, varied concentration, 70:30 Water:Acetonitrile




Choosing the right ion-pairing reagent can lead to better resolution of structural variants of mAbs and other proteins as well as better sensitivity.

### Optimized Middle-Up Analysis of Reduced IgG1 Using the BIOshell™ IgG 1000 Å Diphenyl Column

<b>column:</b>	BIOshell™ IgG 1000 Å Diphenyl, 15 cm x 2.1 mm I.D., 2.7 μm
<b>mobile phase:</b>	[A] Water (0.1% v/v TFA); [B] Acetonitrile (0.1% v/v TFA)
<b>gradient:</b>	30% B to 40% B in 14.0 min
<b>flow rate:</b>	0.4 mL/min
<b>column temp.:</b>	80 °C
<b>detector:</b>	UV, 280 nm
<b>injection:</b>	2 μL
<b>sample:</b>	Reduced Trastuzumab, 400 μg/mL, water


The BIOshell™ IgG 1000 Å Diphenyl column allows for resolution of minor structural variants of the light and heavy chains of mAbs.



### Pore Size Mismatch Can Lead to Significant Losses in Efficiency

<b>column:</b>	BIOshell™ A160 Peptide C18, 15 cm x 2.1 mm I.D., 2.7 μm; BIOshell™ A400 Protein C18, 15 cm x 2.1 mm I.D., 3.4 μm; BIOshell™ IgG 1000 Å C18, 15 cm x 2.1 mm I.D., 2.7 μm;
<b>mobile phase:</b>	[A] Water (0.1% v/v trifluoroacetic acid); [B] 20:80 Water:Acetonitrile (0.085% v/v trifluoroacetic acid)
<b>gradient:</b>	27% B to 60% B in 15 min
<b>flow rate:</b>	0.4 mL/min
<b>column temp.:</b>	60 °C
<b>detector:</b>	UV, 280 nm
<b>injection:</b>	4 μL
<b>sample:</b>	Proteins, varied concentration, water (0.1% v/v trifluoroacetic acid)

1. Ribonuclease A (13.8 kDa)
2. Lysozyme (14.4 kDa)
3. SILu™ Lite SigmaMAb Antibody (~150 kDa)
4. Enolase (46.7 kDa)



Higher efficiencies and better sensitivity can be realized with proper pore diameter selection. Here, the 1000 Å pore diameter is the only one capable of providing good peak of the mAb (peak 3) analyte.